Conflicting results exist about the presence of Mycobacterium avium subspecies paratuberculosis specific IS900 DNA in Crohns' disease tissues.
Dr Schmidt examined IS900 in a large number of gut samples from 100 patients with Crohns' disease and 100 with ulcerative colitis.
|IS900 DNA occurred in both diseased small bowel and colon samples|
The researchers also examined 100 non-inflamed control tissues.
The research team hypothesized that IS900 DNA detection might be associated with distinct clinical phenotypic characteristics in Crohns' disease.
The team examined the prevalence of Mycobacterium avium subspecies paratuberculosis DNA in surgically resected tissues.
The researchers used a mechanical-enzymatic disruption technique and nested IS900 specific polymerase chain reaction.
Crohns' disease patients were stratified according to the criteria of the Vienna classification and other clinical characteristics.
The research team found that IS900 PCR detection rate was significantly higher in Crohns' disease tissue samples than ulcerative colitis or non-IBD specimens.
In Crohns' disease patients, the team detected IS900 DNA in samples from both diseased small bowel as well as from the colon.
The team noted no firm association between Mycobacterium avium subspecies paratuberculosis specific IS900 detection rates.
The research team could establish clinical phenotypic characteristics in Crohns' disease.
However, the researchers observed that corticosteroid medication constituted a factor having a negative influence on IS900 DNA detection rates in Crohns'.
Dr Schmidt's team concludes, “The presence of Mycobacterium avium subspecies paratuberculosis specific IS900 DNA is a predominant feature of Crohns' disease.”
“Therapeutic intervention against Mycobacterium avium subspecies paratuberculosis might represent a potential target for disease mitigation in Crohns' disease.”